A carregar...
Synthesis and identification of GZD856 as an orally bioavailable Bcr-Abl(T315I) inhibitor overcoming acquired imatinib resistance
Bcr-Abl(T315I) induced drug resistance remains a major challenge to chronic myelogenous leukemia (CML) treatment. Herein, we reported GZD856 as a novel orally bioavailable Bcr-Abl(T315I) inhibitor, which strongly suppressed the kinase activities of both native Bcr-Abl and the T315I mutant with IC(50...
Na minha lista:
| Publicado no: | J Enzyme Inhib Med Chem |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Taylor & Francis
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6010122/ https://ncbi.nlm.nih.gov/pubmed/28260399 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/14756366.2016.1250757 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|